Speakers

Government Speaker

Bernard J. Cooney

Assistant United States Attorney
U.S. Attorney's Office, District of New Jersey

Emerging Liability Risks and New Enforcement Priorities Amid Covid-19

April 14, 2021 • 10:15 am

Robert I. Dodge

Assistant Director, FCPA Unit
U.S. Securities and Exchange Commission

Emerging Liability Risks and New Enforcement Priorities Amid Covid-19

April 14, 2021 • 10:15 am

David Last

Assistant Chief, FCPA Unit, Fraud Section, Criminal Division
U.S. Department of Justice

Emerging Liability Risks and New Enforcement Priorities Amid Covid-19

April 14, 2021 • 10:15 am

2021 Conference Co-Chairs

Mariana Kurlat

Senior Director, Anti-Corruption Program Office Lead
Pfizer

Opening Remarks from the Conference Co-Chairs

April 14, 2021 • 10:00 am

Saperstein Jennifer

Jennifer H. Saperstein

Partner
Covington & Burling LLP

Opening Remarks from the Conference Co-Chairs

April 14, 2021 • 10:00 am

Speakers

Ash Aggarwal

Senior Director, Compliance Excellence & Transformation
Astellas Europe

Digital Transformation for Anti-Corruption: Leveraging Data Analytics, Automation and Machine Learning to Prevent and Detect FCPA Violations

April 14, 2021 • 1:00 pm

Parth Chanda

Founder & CEO
Lextegrity

Digital Transformation for Anti-Corruption: Leveraging Data Analytics, Automation and Machine Learning to Prevent and Detect FCPA Violations

April 14, 2021 • 1:00 pm

Derek A. Cohen

Partner
Goodwin Procter

Engaging with Foreign Governments and Providers Amid Covid-19: Special Considerations for the Sale of Medical Supplies and Vaccine Procurement

April 14, 2021 • 3:30 pm

Jill Dailey

Vice President and Chief Compliance Officer
Incyte Inc.

The Newest, Unwritten Rules for Third Party Due Diligence: How to Resolve the Most Industry-Specific Dilemmas

April 14, 2021 • 11:00 am

Megan Gordon

Partner
Clifford Chance

Engaging with Foreign Governments and Providers Amid Covid-19: Special Considerations for the Sale of Medical Supplies and Vaccine Procurement

April 14, 2021 • 3:30 pm

Kathleen Hamann

Kathleen M. Hamann

Partner
Pierce Atwood LLP

The Newest, Unwritten Rules for Third Party Due Diligence: How to Resolve the Most Industry-Specific Dilemmas

April 14, 2021 • 11:00 am

Marc Hennes

Executive Director & Senior Litigation Counsel
Novartis

Reflecting on the 2020 Settlement and a Reimagined Approach to Ethics & Compliance

April 14, 2021 • 12:30 pm

Peter Jensen

Peter G. Jensen

Global Chief Compliance Officer
Arthrex

The Nuances of Sponsorship, Hospitality, and Advisory Board Membership of Foreign Healthcare Providers: What Companies are Now Doing to Strengthen Compliance

April 14, 2021 • 5:15 pm

Kate Kiesel

Global Health Care Compliance Officer
LifeScan

Digital Transformation for Anti-Corruption: Leveraging Data Analytics, Automation and Machine Learning to Prevent and Detect FCPA Violations

April 14, 2021 • 1:00 pm

James M. Koukios

Partner
Morrison & Foerster LLP

Reflecting on the 2020 Settlement and a Reimagined Approach to Ethics & Compliance

April 14, 2021 • 12:30 pm

Joseph Mack

Senior Assistant General Counsel, Compliance and Investigations
Bayer U.S.

How to Measure the Effectiveness of Your Compliance Program: Industry-Specific Considerations

April 14, 2021 • 2:15 pm

David H. Resnicoff

Partner
Riley Safer Holmes & Cancila LLP

How to Measure the Effectiveness of Your Compliance Program: Industry-Specific Considerations

April 14, 2021 • 2:15 pm

Mona Peterson Rosow

Sr. Director, Global Auditing & Monitoring
Medtronic

How to Measure the Effectiveness of Your Compliance Program: Industry-Specific Considerations

April 14, 2021 • 2:15 pm

Jessica S. Pill

VP, Chief Compliance Officer
Boston Scientific

Determining When (and When Not) to Proceed with Clinical Trials Abroad: Managing Unique, Evolving Bribery Risk Factors

April 14, 2021 • 4:30 pm

William Simmons

Head of Global Investigations; Associate Director, Ethics & Compliance
Lonza

How to Measure the Effectiveness of Your Compliance Program: Industry-Specific Considerations

April 14, 2021 • 2:15 pm

Robert N. Sikellis

Vice President & Global Head of Investigations
Novartis

Reflecting on the 2020 Settlement and a Reimagined Approach to Ethics & Compliance

April 14, 2021 • 12:30 pm

William B.F. Steinman

Senior Partner
Steinman & Rodgers LLP

Determining When (and When Not) to Proceed with Clinical Trials Abroad: Managing Unique, Evolving Bribery Risk Factors

April 14, 2021 • 4:30 pm

Patrick F. Stokes

Partner
Gibson, Dunn & Crutcher LLP

The Nuances of Sponsorship, Hospitality, and Advisory Board Membership of Foreign Healthcare Providers: What Companies are Now Doing to Strengthen Compliance

April 14, 2021 • 5:15 pm

Nancy S. Travis

Acting Chief of Staff
Vice President, Global Compliance & Governance
Advanced Medical Technology Association (AdvaMed)

The Newest, Unwritten Rules for Third Party Due Diligence: How to Resolve the Most Industry-Specific Dilemmas

April 14, 2021 • 11:00 am